Platform Development & Preclinical Research

About Kyron.bio

Kyron.bio is an early-stage, Paris-based biotech focused on engineering the glycosylation of therapeutic proteins to unlock superior drug properties. The company has developed a novel cell line engineering and structure-guided design platform to precisely control N-glycan patterns, aiming to overcome key challenges in antibody therapeutics such as immunogenicity and pharmacokinetics. Backed by a €5.5M seed round and strategic partnerships, Kyron.bio is building its team and advancing its platform towards preclinical development from its base at the Paris Biotech Santé incubator.

Therapeutic Areas